In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Remimazolam should not be used in patients less than 18 years of age. Remimazolam may cause confusion and over-sedation in the elderly; elderly patients generally should be observed closely.
A case of intravenous line occlusion has been reported when using Acetated Ringer's solution and remimazolam (https://doi.org/10.1016/j.jclinane.2021.110190).
REMIMAZOLAM HAS BEEN ASSOCIATED WITH HYPOXIA, BRADYCARDIA, AND HYPOTENSION. CONCOMITANT USE OF BENZODIAZEPINES WITH OPIOID ANALGESICS MAY RESULT IN PROFOUND SEDATION, RESPIRATORY DEPRESSION, COMA, AND DEATH. THE SEDATIVE EFFECT OF INTRAVENOUS REMIMAZOLAM CAN BE ACCENTUATED BY CONCOMITANTLY ADMINISTERED CNS DEPRESSANT MEDICATIONS, INCLUDING OTHER BENZODIAZEPINES AND PROPOFOL.
See full prescribing information for complete boxed warning
Please login to view the rest of this drug profile.